Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
BioCryst Pharmaceuticals, Inc. (NQ: BCRX)
1.710 USD  -0.020 (-1.16%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about BioCryst Pharmaceuticals, Inc.
 
< Previous 1 2 3 4 5 6 7 8 Next >
Improving Trend in for FDA First Cycle Review Approvals a Major Factor for Biotech Industry's Success in 2012
November 12, 2012
Five Star Equities Provides Stock Research on BioCryst Pharmaceuticals and Catalyst Pharmaceutical Read More
from Marketwired News Releases
BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective against Yellow Fever in a Preclinical Disease Model
November 12, 2012
from Business Wire News Releases
Free Research Reports on BCRX, CPRX, ES and MWW Issued by the Bedford Report
November 09, 2012
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
BioCryst Provides Corporate Update and Reports Third Quarter 2012 Financial Results
November 08, 2012
from Business Wire News Releases
BioCryst Announces Outcome from the Peramivir Phase 3 Interim Analysis
November 07, 2012
from Business Wire News Releases
BioCryst to Report Third Quarter 2012 Financial Results on November 8, 2012
November 01, 2012
from Business Wire News Releases
BioCryst Provides Update Regarding BCX5191 Development Plan Following Discussion With FDA
October 30, 2012
from Business Wire News Releases
Free Reports on BioCryst Pharmaceuticals, Overseas Shipholding, Prospect Global Resources and Monster Beverage Provided by the Bedford Report
October 23, 2012
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the CAPITAL NEWS CIRCUIT Read More
from Marketwired News Releases
FDA Considering Allowing Developers of Drugs for Deadly or Debilitating Diseases to Conduct Smaller, Faster Clinical Trials
October 23, 2012
The Paragon Report Provides Stock Research on Puma Biotechnology and BioCryst Pharmaceuticals Read More
from Marketwired News Releases
BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge
October 18, 2012
from Business Wire News Releases
BioCryst Provides Corporate Update and Reports Second Quarter 2012 Financial Results
August 02, 2012
from Business Wire News Releases
BioCryst Announces Positive Results from Two Ulodesine Phase 2 Trials in Patients with Gout
July 24, 2012
from Business Wire News Releases
BioCryst to Report Second Quarter 2012 Financial Results on August 2, 2012
July 19, 2012
from Business Wire News Releases
BioCryst to Present at the 7th Annual JMP Securities Healthcare Conference
June 28, 2012
from Business Wire News Releases
Biotech Industry Showing Impressive Gains for Investors in 2012
June 08, 2012
The Paragon Report Provides Stock Research on BioCryst and Threshold Read More
from Marketwired News Releases
BioCryst Presents Results from Its BCX4208 Gout Program at the Annual European Congress of Rheumatology
June 06, 2012
from Business Wire News Releases
BioCryst to Present at Two Upcoming Investor Conferences
May 22, 2012
from Business Wire News Releases
BioCryst Provides Corporate Update and Reports First Quarter 2012 Financial Results
May 07, 2012
from Business Wire News Releases
BioCryst to Present at Two Upcoming Investor Conferences
May 01, 2012
from Business Wire News Releases
BioCryst to Report First Quarter 2012 Financial Results on May 7, 2012
April 25, 2012
from Business Wire News Releases
BioCryst to Present at Two Upcoming Investor Conferences
February 23, 2012
from Business Wire News Releases
BioCryst Reports Fourth Quarter and Full Year 2011 Financial Results
February 16, 2012
from Business Wire News Releases
BioCryst Announces Promising Results from Preclinical Studies of BCX5191 for Hepatitis C
February 15, 2012
from Business Wire News Releases
BioCryst to Announce Fourth Quarter and Full Year 2011 Financial Results on February 16, 2012
February 06, 2012
from Business Wire News Releases
Nancy Hutson Appointed to BioCryst’s Board of Directors
January 19, 2012
from Business Wire News Releases
BioCryst Announces Positive Results from Its Ongoing BCX4208 Phase 2B Study in Patients with Gout
January 08, 2012
from Business Wire News Releases
BioCryst Pharmaceuticals Presents New BCX4208 Gout Data at the 2011 ACR/ARHP Annual Scientific Meeting
November 08, 2011
from Business Wire News Releases
BioCryst Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2011 Financial Results
November 02, 2011
from Business Wire News Releases
BioCryst Pharmaceuticals Announces New BCX4208 Gout Data Has Been Accepted as a Late-Breaker Oral Presentation at the ACR/ARHP 2011 Annual Scientific Meeting
October 24, 2011
from Business Wire News Releases
BioCryst Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 2, 2011
October 19, 2011
from Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here